Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream with Mometasone Furoate 0.1%

Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders. The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators. Using the vasoconstrictor assay, a strong blanching effect of the new cream (called Mometasone cream) comparable to that of a mometasone comparator, a fatty cream with mometasone furoate 0.1%, could be demonstrated. Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator. Using the psoriasis plaque test, a strong antipsoriatic effect comparable to that of the mometasone comparator was found for Mometasone cream after 12 days of occlusive treatment. A nearly identical reduction in the mean infiltrate thickness and similar mean AUC values were noted with both formulations confirmed by clinical assessment data. The noninferiority of Mometasone cream to its active comparator with re-spect to the AUC of change to baseline in infiltrate thickness was demonstrated. Both medications were well tolerated. Overall, Mometasone cream and the mometasone comparator showed similar efficacy and tolerability. Mometasone cream, in addition to its high potency and good tolerability, provides the properties of a light cream, which might make this new medication particularly suitable for application on acutely inflamed and sensitive skin. Copyright (C) 2012 S. Karger AG, Base

Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay

Introduction: We report on a double-blind, vehicle-controlled, single-center confirmatory study with random assignment. The purpose of the study was to investigate the topical bioavailability of different topical corticosteroid formulations in healthy human beings focussing on desoximetasone (DM). Materials and Methods: Two DM 0.25% formulations {[}ointment (DM-o) and fatty ointment (DM-fo, water-free); class III corticosteroids], the corresponding active ingredient-free vehicles and three comparators of different strength {[}clobetasol propionate 0.05% (CP 0.05%), fatty ointment, class IV; hydrocortisone (HC) 1%, fatty ointment, class I, and betamethasone (BM) 0.05%, fatty ointment, class III] were tested using the vasoconstriction assay. The degree of vasoconstriction (blanching) in the treatment field was compared to the one found in untreated control fields using chromametric measurements and clinical assessment. Results/Conclusion: DM-o 0.25%, DM-fo 0.25% and BM 0.05% showed similar vasoconstrictive potential, i.e., clear blanching. In fact, both DM preparations were proven to be non-inferior to BM 0.05%, while CP 0.05% was found a little less active. HC 1.0% and the DM vehicles showed no clear-cut vasoconstrictive effect. No adverse events related to the study medications were observed. Good topical bioavailability of both DM formulations was detected by chromametric measurement and clinical assessment. Copyright (C) 2008 S. Karger AG, Basel

Small-scale magnetic buoyancy and magnetic pumping effects in a turbulent convection

We determine the nonlinear drift velocities of the mean magnetic field and nonlinear turbulent magnetic diffusion in a turbulent convection. We show that the nonlinear drift velocities are caused by the three kinds of the inhomogeneities, i.e., inhomogeneous turbulence; the nonuniform fluid density and the nonuniform turbulent heat flux. The inhomogeneous turbulence results in the well-known turbulent diamagnetic and paramagnetic velocities. The nonlinear drift velocities of the mean magnetic field cause the small-scale magnetic buoyancy and magnetic pumping effects in the turbulent convection. These phenomena are different from the large-scale magnetic buoyancy and magnetic pumping effects which are due to the effect of the mean magnetic field on the large-scale density stratified fluid flow. The small-scale magnetic buoyancy and magnetic pumping can be stronger than these large-scale effects when the mean magnetic field is smaller than the equipartition field. We discuss the small-scale magnetic buoyancy and magnetic pumping effects in the context of the solar and stellar turbulent convection. We demonstrate also that the nonlinear turbulent magnetic diffusion in the turbulent convection is anisotropic even for a weak mean magnetic field. In particular, it is enhanced in the radial direction. The magnetic fluctuations due to the small-scale dynamo increase the turbulent magnetic diffusion of the toroidal component of the mean magnetic field, while they do not affect the turbulent magnetic diffusion of the poloidal field.Comment: 13 pages, 4 figure, REVTEX4, Geophysical and Astrophysical Fluid Dynamics, in pres